{"id":63176,"date":"2026-05-29T01:03:00","date_gmt":"2026-05-28T23:03:00","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/pfizer-and-innovent-biologics-enter-global-strategic-collaboration-to-accelerate-development-of-innovative-oncology-medicines\/"},"modified":"2026-05-29T01:03:00","modified_gmt":"2026-05-28T23:03:00","slug":"pfizer-and-innovent-biologics-enter-global-strategic-collaboration-to-accelerate-development-of-innovative-oncology-medicines","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/pfizer-and-innovent-biologics-enter-global-strategic-collaboration-to-accelerate-development-of-innovative-oncology-medicines\/","title":{"rendered":"Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines"},"content":{"rendered":"
\n

NEW YORK & SAN FRANCISCO & SUZHOU, China–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new breakthrough early-stage and de novo<\/i> cancer medicines. The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates (ADCs) with novel differentiated payloads and multi-specific antibodies with differentiated immune-engaging features and unique designs.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe strategic collaboration brings together Pfizer\u2019s deep scientific expertise, global clinical development capabilities, regulatory leadership and commercial scale with Innovent\u2019s scientific discovery and clinical capabilities in oncology innovation, which are highly complementary to each company\u2019s core areas of interest.<\/p>\n

\nThe agreement spans a portfolio of 12 programs comprising eight Innovent-originated early-stage programs and four Pfizer-proposed discovery programs. The companies will co-develop and share costs for select programs as they advance these programs through clinical development.<\/p>\n

\n\u201cAt Pfizer, everything we do starts with patients and the urgency to change what\u2019s possible for people living with cancer,\u201d said Jeff Legos, Chief Oncology Officer, Pfizer. \u201cThis collaboration brings together two highly complementary engines of innovation with a shared ambition to move faster, go further and deliver truly transformative medicines to patients who are waiting. By combining Innovent\u2019s discovery and early clinical development with Pfizer\u2019s global research and development and commercialization capabilities, we have an opportunity not only to strengthen our pipeline, but to accelerate the delivery of breakthroughs that can redefine standards of care and make a meaningful difference in patients\u2019 lives.\u201d<\/p>\n

\n\u201cThis agreement brings together best-in-industry expertise of Pfizer and Innovent to advance novel cancer medicines to patients at a global scale,\u201d said Dr. Hui Zhou, Chief R&D Officer (Oncology Pipeline) of Innovent. \u201cBy leveraging both companies’ complementary resources, we can develop our early-stage oncology pipeline with greater speed and impact to help bring innovative therapies to patients more efficiently worldwide. Furthermore, co-developing and co-commercializing key projects in the U.S. and Europe expands Innovent\u2019s global reach. At Innovent, we are laying the foundation for a truly global oncology platform that can deliver meaningful and lasting benefits for patients around the world.\u201d<\/p>\n

\nAccording to the agreement, Innovent will conduct development of these programs through Phase 1, powered by its proprietary discovery engine and robust early clinical capabilities, after which Pfizer will lead future global development. The agreement also sets out the following licensing and commercialization structure:<\/p>\n